Figure 1.
TNIK was upregulated in castration-resistant prostate cancer
(A) Heatmap of the genome-wide transcript profile between (CR-LNCaP) castration tumors and (HS-LNCaP) uncastration tumors.
(B) GO analysis of transcript profile.
(C) qPCR detects mRNA expression of TNIK in (CR-LNCaP) castration tumors and (HS-LNCaP) uncastration tumors (p < 0.05). Data are represented as mean ± SD.
(D) Clinical specimens of benign prostate hyperplasia (BPH), hormone native, and CRPC were analyzed by IHC for TNIK expression. Scale bars: 200 μm. H-score of TNIK immunoreactivity in HSPC, CRPC, and their paracancerous tissues. Data were presented as median (interquartile range). Data are represented as mean ± SD. The hash symbol indicates significantly different from Para (HSPC) group (p < 0.05); an asterisk indicates significantly different from Para (CRPC) group (p < 0.05).
